Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 7/20 | 0.38 |
| ▸ | HTR6 | P50406 | 7/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 2/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.34 |
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4272021 | 0.95 | MAPKAPK2 (0.38) | HTR7HTR6MAPKAPK2MTORHDAC1 | |
| Hydrochloric Acid SCHEMBL4269768 | 0.82 | MAPKAPK2 (0.39) | MAPKAPK2MTORHDAC1 | |
| SCHEMBL1660747 | 0.81 | MAPKAPK2 (0.43) | MAPKAPK2MTORHDAC1 | |
| Trifluoroacetic Acid SCHEMBL4267121 | 0.79 | MAPKAPK2 (0.44) | MAPKAPK2MTORHDAC1 | |
| SCHEMBL6795012 | 0.77 | KDM4E (0.40) | FAAH | |
| SCHEMBL6793266 | 0.77 | MAPKAPK2 (0.41) | MAPKAPK2MTORHDAC1 | |
| Hydrochloric Acid SCHEMBL4263089 | 0.76 | CDK2 (0.44) | MAPKAPK2MTORHDAC1 | |
| Hydrochloric Acid SCHEMBL1655155 | 0.75 | HDAC1 (0.42) | MAPKAPK2MTORHDAC1 | |
| SCHEMBL6788934 | 0.74 | MAPKAPK2 (0.40) | MAPKAPK2MTORHDAC1 | |
| SCHEMBL6794525 | 0.74 | MAPKAPK2 (0.41) | MAPKAPK2MTORHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | claimed |
| US-9023787-B2 | MAPKAP kinase-2 as a specific target for blocking proliferation of P53-defective | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-05-05 | — | — | US | disclosed |
| US-20140037755-A1 | Mapkap Kinase-2 as a Specific Target for Blocking Proliferation of P53-Defective Cells | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2014-02-06 | — | — | US | disclosed |
| US-8440610-B2 | Mapkap kinase-2 as a specific target for blocking proliferation of P53-defective cells | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-05-14 | — | — | US | disclosed |
| US-20120252737-A1 | Methods for Diagnosing and Treating Cancer | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-10-04 | — | — | US | disclosed |
| US-20090181468-A1 | Methods and compositions for treating cellular proliferative diseases | YAFFE MICHAEL B | 2009-07-16 | — | — | US | disclosed |
| US-20090010927-A1 | Mapkap kinase-2 as a specific target for blocking proliferation of P53-defective cells | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-01-08 | — | — | US | disclosed |
| EP-1824498-A2 | METHODS AND COMPOSITIONS FOR TREATING CELLULAR PROLIFERATIVE DISEASES | THE MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2007-08-29 | — | — | EP | disclosed |
| US-20060115453-A1 | Methods and compositions for treating cellular proliferative diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-06-01 | — | — | US | disclosed |
| WO-2006053315-A2 | METHODS AND COMPOSITIONS FOR TREATING CELLULAR PROLIFERATIVE DISEASES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060115453-A1 | Methods and compositions for treating cellular proliferative diseases | MKI67, TP53, CCNC | HTR7 3832/4885HTR6 3539/4885MAPKAPK2 1486/4885 |
| US-20140037755-A1 | Mapkap Kinase-2 as a Specific Target for Blocking Proliferation of P53-Defective Cells | MAPKAPK2, MAPKAP1, MAP3K2 | HTR7 4554/4885HTR6 4466/4885MAPKAPK2 1/4885 |
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | HTR7 1805/4885HTR6 2833/4885MAPKAPK2 2/4885 |
| US-20090010927-A1 | Mapkap kinase-2 as a specific target for blocking proliferation of P53-defective cells | MAPKAPK2, MAPKAP1, MAP3K2 | HTR7 4554/4885HTR6 4466/4885MAPKAPK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.